Literature DB >> 31156849

Optimal dosing of angiotensin-converting enzyme inhibitors and β-blockers for acute coronary syndrome: up-titration remains a challenge.

Natasha Sharma1, Rani Khatib1, Nadir Elamin1, James Eaden1, Chiat Ee Choong1, Chris Jones1, Muzahir Tayebjee1.   

Abstract

OBJECTIVES: Suboptimal dosing of angiotensin-converting enzyme inhibitors and β-blockers limits the mortality benefit for acute coronary syndrome patients. Recent National Institute for Health and Care Excellence (NICE) guidelines emphasise prompt initiation and up-titration from inpatient to community care to achieve this. The aim of this study was to assess the impact of simple interventions on inpatient and community up-titration of bisoprolol and ramipril for acute coronary syndrome patients admitted to Leeds General Infirmary.
METHODS: An initial prospective audit of 37 acute coronary syndrome patients admitted to Leeds General Infirmary in January 2013 assessed inpatient up-titration of bisoprolol and ramipril, discharge advice and doses at 6 weeks after discharge. Following a collective multidisciplinary effort with education, posters and discharge advice templates, a re-audit of 34 acute coronary syndrome patients admitted from November to December 2014 assessed the impact of these interventions. The independent samples t test was used to compare the mean difference between doses of ramipril and bisoprolol from initiation to discharge to dose at 6 weeks after discharge before and after intervention.
RESULTS: There was a statistically significant improvement in the mean difference from initiation to discharge dose for both ramipril and bisoprolol (p=0.012 and p=0.017, respectively). However, there was little difference in community up-titration despite a 68% improvement in discharge advice.
CONCLUSIONS: Simple multidisciplinary interventions improved inpatient up-titration of ramipril and bisoprolol but continued up-titration to achieve the target doses remains a challenge in primary care. Acute coronary syndrome patients are precluded from maximum mortality benefit due to suboptimal dosing after discharge.

Entities:  

Keywords:  acute coronary syndrome; angiotensin-converting enzyme inhibitor; beta-blocker; medicines optimisation; up-titration

Year:  2015        PMID: 31156849      PMCID: PMC6451458          DOI: 10.1136/ejhpharm-2015-000783

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  4 in total

1.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrøm; Niels Gadsbøll; Pernille Buch; Jens Friberg; Søren Rasmussen; Lars Køber; Steen Stender; Mette Madsen; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2006-01-06       Impact factor: 29.983

2.  The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions.

Authors:  A S Hall; C Winter; S M Bogle; A F Mackintosh; G D Murray; S G Ball
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

3.  Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.

Authors:  M A Pfeffer; S C Greaves; J M Arnold; R J Glynn; F S LaMotte; R T Lee; F J Menapace; E Rapaport; P M Ridker; J L Rouleau; S D Solomon; C H Hennekens
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

4.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

Authors: 
Journal:  Circulation       Date:  1998-06-09       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.